Accuray Inc. yesterday announced that it has surpassed 600 installations of its CyberKnife Robotic Radiosurgery System and TomoTherapy System globally. The numbers were presented at the 30th annual J.P. Morgan Healthcare Conference in San Francisco by Accuray CEO Euan Thompson.
Accuray is a Sunnyvale, CA company that focuses on developing and manufacturing devices intended for radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. Their CyberKnife and TomoTherapy systems have assisted over 200,000 patients worldwide.
With over 600 installations in 33 countries in approximately ten years, Accuray has solidified their marketplace position. Accuray is currently pursuing opportunities that will see replacement units taking over for the earliest installed CyberKnife and TomoTherapy systems. With a growing demand for effective and efficient radiation oncology treatments, Accuray seems confident that momentum will continue to further push year-over-year growth.
Euan S. Thomson, president and CEO of Accuray, said, “Accuray is committed to advancing our product lines to meet the ever-changing needs of our customer base, as well as the patients fighting cancer. The proven advantages of Accuray’s treatment systems are behind the growing global adoption of both the CyberKnife and TomoTherapy systems by new as well as existing customers. Our proven track record solidifies Accuray’s position in the growing radiation oncology market.”
Raj Denhoy, managing director, equity research at Jefferies & Co., said, “Through the acquisition of TomoTherapy, Accuray is well positioned with two cutting edge and complementary technologies in a growing radiation oncology market. With an established and growing installed customer base, we anticipate continued good growth driven by both competitive wins as well as replacements.”
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html